Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A prospective flexible-dose study of paliperidone palmitate in nonacute but symptomatic patients with schizophrenia previously unsuccessfully treated with oral antipsychotic agents.
Schreiner A, Bergmans P, Cherubin P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Hargarter L. Schreiner A, et al. Among authors: vidailhet p. Clin Ther. 2014 Oct 1;36(10):1372-88.e1. doi: 10.1016/j.clinthera.2014.08.014. Epub 2014 Oct 23. Clin Ther. 2014. PMID: 25444566 Free article. Clinical Trial.
Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.
Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A. Hargarter L, et al. Among authors: vidailhet p. Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:1-7. doi: 10.1016/j.pnpbp.2014.11.006. Epub 2014 Nov 15. Prog Neuropsychopharmacol Biol Psychiatry. 2015. PMID: 25448776 Free article. Clinical Trial.
Prevalence of and Risk Factors for Extrapyramidal Side Effects of Antipsychotics: Results From the National FACE-SZ Cohort.
Misdrahi D, Tessier A, Daubigney A, Meissner WG, Schurhoff F, Boyer L, Godin O, Bulzacka E, Aouizerate B, Andrianarisoa M, Berna F, Capdevielle D, Chereau-Boudet I, D'Amato T, Dubertret C, Dubreucq J, Faget-Agius C, Lançon C, Mallet J, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Fond G; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Misdrahi D, et al. Among authors: vidailhet p. J Clin Psychiatry. 2019 Jan 8;80(1):18m12246. doi: 10.4088/JCP.18m12246. J Clin Psychiatry. 2019. PMID: 30695288 Free article.
Validation study of the Medication Adherence Rating Scale. Results from the FACE-SZ national dataset.
Fond G, Boyer L, Boucekine M, Aden LA, Schürhoff F, Tessier A, Andrianarisoa M, Berna F, Brunel L, Capdevielle D, Chereau I, Mallet J, Denizot H, Dorey JM, Dubertret C, Dubreucq J, Faget C, Gabayet F, Rey R, Richieri R, Passerieux C, Schandrin A, Urbach M, Vidailhet P, Llorca PM, Misdrahi D; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Fond G, et al. Among authors: vidailhet p. Schizophr Res. 2017 Apr;182:84-89. doi: 10.1016/j.schres.2016.10.023. Epub 2016 Oct 24. Schizophr Res. 2017. PMID: 27789187
Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort.
Fond G, Boyer L, Berna F, Godin O, Bulzacka E, Andrianarisoa M, Brunel L, Aouizerate B, Capdevielle D, Chereau I, Coulon N, D'Amato T, Dubertret C, Dubreucq J, Faget C, Leignier S, Lançon C, Mallet J, Misdrahi D, Passerieux C, Rey R, Schandrin A, Urbach M, Vidailhet P, Leboyer M, Schürhoff F, Llorca PM; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) group. Fond G, et al. Among authors: vidailhet p. Br J Psychiatry. 2018 Aug;213(2):464-470. doi: 10.1192/bjp.2018.87. Epub 2018 Jun 6. Br J Psychiatry. 2018. PMID: 29871707
Metabolic Syndrome and Illness Severity Predict Relapse at 1-Year Follow-Up in Schizophrenia: The FACE-SZ Cohort.
Godin O, Leboyer M, Schürhoff F, Llorca PM, Boyer L, Andre M, Andrianarisoa M, Aouizerate B, Berna F, Capdevielle D, Chereau I, Dorey JM, Dubertret C, Dubreucq J, Faget C, Lancon C, Leignier S, Mallet J, Misdrahi D, Passerieux C, Rey R, Roux P, Vidailhet P, Costagliola D, Fond G; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Group. Godin O, et al. Among authors: vidailhet p. J Clin Psychiatry. 2018 Sep 18;79(6):17m12007. doi: 10.4088/JCP.17m12007. J Clin Psychiatry. 2018. PMID: 30257079
Metacognitive training for schizophrenia: a multicentre randomised controlled trial.
Briki M, Monnin J, Haffen E, Sechter D, Favrod J, Netillard C, Cheraitia E, Marin K, Govyadovskaya S, Tio G, Bonin B, Chauvet-Gelinier JC, Leclerc S, Hodé Y, Vidailhet P, Berna F, Bertschy AZ, Vandel P. Briki M, et al. Among authors: vidailhet p. Schizophr Res. 2014 Aug;157(1-3):99-106. doi: 10.1016/j.schres.2014.06.005. Epub 2014 Jun 24. Schizophr Res. 2014. PMID: 24972754 Clinical Trial.
Early and very early-onset schizophrenia compared with adult-onset schizophrenia: French FACE-SZ database.
Coulon N, Godin O, Bulzacka E, Dubertret C, Mallet J, Fond G, Brunel L, Andrianarisoa M, Anderson G, Chereau I, Denizot H, Rey R, Dorey JM, Lançon C, Faget C, Roux P, Passerieux C, Dubreucq J, Leignier S, Capdevielle D, André M, Aouizerate B, Misdrahi D, Berna F, Vidailhet P, Leboyer M, Schürhoff F. Coulon N, et al. Among authors: vidailhet p. Brain Behav. 2020 Feb;10(2):e01495. doi: 10.1002/brb3.1495. Epub 2020 Jan 7. Brain Behav. 2020. PMID: 31908151 Free PMC article.
Dosing antipsychotics in special populations of patients with schizophrenia: severe psychotic agitation, first psychotic episode and elderly patients.
Mouaffak F, Ferreri F, Bourgin-Duchesnay J, Baloche E, Blin O, Vandel P, Garay RP, Vidailhet P, Corruble E, Llorca PM. Mouaffak F, et al. Among authors: vidailhet p. Expert Opin Pharmacother. 2021 Dec;22(18):2507-2519. doi: 10.1080/14656566.2021.1958781. Epub 2021 Aug 17. Expert Opin Pharmacother. 2021. PMID: 34338130 Review.
104 results